Expert consensus on RhD blood group testing strategies in blood transfusion compatibility testing laboratories / 中国输血杂志

ABSTRACT

RhD antigen is the most immunogenic antigens in the Rh blood group system and can cause hemolytic transfusion reactions (HTRs) and severe hemolytic disease of the fetus and newborn (HDFN). RhD-negative red blood cell (RBC) is a scarce resource in China, and RhD-negative patients face challenges in timely blood transfusion. For different populations that were initially negative for RhD (saline method), what techniques should be used, how to issue test report and when should " Asian type" DEL (RHD*01EL.01, c.1227G>A) be identified are the confusions of blood transfusion workers in the process of clinical blood supply. More than 200 technical experts discussed and reached a consensus on blood transfusion compatibility testing for Chinese population. The purpose of the consensus is to further standardize and refine the RhD blood group testing strategy, provide technical support for achieving accurate blood transfusion for patients with different RhD blood groups, continuously improve the levels of prevention and treatment for RhD-HTRs and RhD-HDFN, and lay a foundation for the future development of industry standards concerning RhD blood group testing strategy.